Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts
Altimmune, Inc. is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide and a capital-raising backdrop that can quickly change the stock's risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment.